Cargando…

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pottier, Charles, Fresnais, Margaux, Gilon, Marie, Jérusalem, Guy, Longuespée, Rémi, Sounni, Nor Eddine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140093/ https://www.ncbi.nlm.nih.gov/pubmed/32244867 http://dx.doi.org/10.3390/cancers12030731

Ejemplares similares

Desorption Kinetics Evaluation for the Development of Validated Desorption Electrospray Ionization-Mass Spectrometric Assays for Drug Quantification in Tissue Sections
por: Fresnais, Margaux, et al.
Publicado: (2023)

Quantification of Biologically Active DNA Alkylation in Temozolomide-Exposed Glioblastoma Cell Lines by Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry: Method Development and Recommendations for Validation
por: Fresnais, Margaux, et al.
Publicado: (2023)

Development and Validation of an LC–MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus
por: Fresnais, Margaux, et al.
Publicado: (2020)

Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay
por: Fresnais, Margaux, et al.
Publicado: (2020)

Important Requirements for Desorption/Ionization Mass Spectrometric Measurements of Temozolomide-Induced 2′-Deoxyguanosine Methylations in DNA
por: Fresnais, Margaux, et al.
Publicado: (2023)

Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence
por: Luis, Géraldine, et al.
Publicado: (2021)

Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance
por: Azam, Aurelien, et al.
Publicado: (2022)

Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma
por: Fresnais, Margaux, et al.
Publicado: (2021)

Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices—A Practical Example
por: Fresnais, Margaux, et al.
Publicado: (2022)

Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives
por: Fresnais, Margaux, et al.
Publicado: (2021)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors Target B Lymphocytes
por: Upfold, Nikki Lyn Esnardo, et al.
Publicado: (2023)

MT-MMPS as Regulators of Vessel Stability Associated with Angiogenesis
por: Sounni, Nor Eddine, et al.
Publicado: (2011)

MT4-MMP: The GPI-Anchored Membrane-Type Matrix Metalloprotease with Multiple Functions in Diseases
por: Yip, Cassandre, et al.
Publicado: (2019)

Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections
por: Fresnais, Margaux, et al.
Publicado: (2022)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
por: Chen, Chenglong, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib
por: Yip, Cassandre, et al.
Publicado: (2017)

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
por: Puliafito, Ivana, et al.
Publicado: (2022)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
por: Wen, Tingyu, et al.
Publicado: (2020)

Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo
por: Yu, Tao, et al.
Publicado: (2021)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
por: Park, Hyunjung, et al.
Publicado: (2022)

New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
por: Lin, Nancy U, et al.
Publicado: (2004)

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
por: Hill, Andrew, et al.
Publicado: (2016)

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
por: Shen, Guoshuang, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
por: Lorenzo-Vizcaya, Ana, et al.
Publicado: (2020)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
por: Xu, Wenjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3bcmi3pvtblbavqqgkv1kj9if5